Renowned pharmaceutical scientist will collaborate with JGU professor to reduce side effects of chemotherapy

The internationally famend pharmaceutical scientist Professor Hans Lennernäs of Uppsala College has been given a Humboldt Analysis Award price EUR 60,000 by the Alexander von Humboldt Basis. Amongst different issues, he will be utilizing the award funding to spend six months as a visiting scholar at Johannes Gutenberg College Mainz (JGU) to be part of Professor Peter Langguth of the Institute of Pharmaceutical and Biomedical Sciences, who nominated him for the prize.

Hans Lennernäs is among the many world’s main specialists within the area of pharmaceutical science. His distinctive translational tasks have repeatedly demonstrated how findings from pure biomedical analysis can efficiently outcome within the improvement of purposes that can be utilized in follow. We’re each delighted that the Alexander von Humboldt Basis is thus offering us with the chance to intensify our current collaboration.”

Professor Peter Langguth, Institute of Pharmaceutical and Biomedical Sciences

Lennernäs is anticipated to arrive in Mainz this fall. He and Langguth will work collectively to examine methods to mitigate the standard undesirable effects skilled by sufferers present process chemotherapy for most cancers.

“Following the administration of chemotherapeutic medication, the outcome can usually be mucosal irritation or injury to the digestive tract. Such side effects could be so extreme that the drug dosage wants to be diminished, in flip decreasing their effectiveness in opposition to most cancers,” Langguth identified. “Our purpose is to establish lively substances that will counteract these adversarial reactions after which discover whether or not it’s doable to develop medication primarily based on these substances. Our groups completely complement one another in phrases of their experience. Hans Lennernäs’ analysis workforce has in depth data of the therapeutic processes of intestinal tissue, whereas in Mainz we all know a terrific deal about how we want to produce medication to be sure that their lively components are transported exactly to the websites within the physique the place they’ll greatest exert their effects.”

Langguth’s and Lennernäs’ analysis will complement the work of the JGU Collaborative Analysis Middle on Nano-Dimensional Polymer Therapeutics for Tumor Remedy, wherein Langguth is a co-project coordinator.

Hans Lennernäs has been Professor of Pharmaceutical Biosciences at Uppsala College, Sweden, since 2000. His present analysis focuses on the event of medication for prostate and liver most cancers. He has revealed greater than 240 analysis papers, supervised 28 doctoral college students, and obtained a quantity of nationwide and worldwide awards, together with that of the Academy of Pharmaceutical Sciences within the UK. His work as a lead scientist in a venture for the U.S. Meals & Drug Administration (FDA) on the College of Michigan and on the Swedish Medical Merchandise Company from 1992 to 2000 has earned him worldwide recognition. Within the venture, Lennernäs performed a key function in creating the Biopharmaceutics Classification System (BCS), which differentiates between medication on the premise of their solubility and permeability. This permits medical prescribers to choose from multisource drug merchandise with equivalent lively contents (e.g., generics) and permits pharmacists to dispense extra cost-efficient merchandise with related high quality.

The Alexander von Humboldt Basis offers its Humboldt Analysis Award yearly to up to 100 main worldwide researchers from exterior Germany whose general achievements throughout their careers to date have been significantly excellent. It’s doable to nominate researchers for an award whose discoveries, findings, or theories have had a long-lasting impact on their self-discipline past their instant analysis space and who’re anticipated to proceed producing distinctive analysis sooner or later. Award winners are invited to conduct a analysis venture of their selection at a analysis establishment in Germany in cooperation with specialist colleagues there for a interval of up to one yr. Nominations could be submitted by researchers at analysis establishments in Germany.